Q-omics provides the consensus-scored MYO5BP3 profile across patient tissues and cancer cell-line models. MYO5BP3 expression is associated with patient survival in 16 of 34 cancer types, with the highest sampling consensus in LUAD. Among the 18 cancer types available for tumor–normal comparison, MYO5BP3 is differentially expressed in 2, with the highest sampling consensus in COAD. Additionally, MYO5BP3 RNA expression shows 4,987 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight LUAD, COAD, and STAD as cancer lineages where MYO5BP3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MYO5BP3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MYO5BP3 survival associations across molecular data types. MYO5BP3 RNA expression shows survival associations in the most cancer types (16). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MYO5BP3 RNA expression–survival associations across cancer types. High MYO5BP3 expression shows unfavorable associations in LUAD, CHOL, UVM and ACC, but favorable associations in BLCA and LAML. The LUAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LUAD as the clearest survival context for MYO5BP3 RNA expression.
This table summarizes MYO5BP3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 2. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for MYO5BP3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MYO5BP3 shows higher tumor expression in COAD and KICH. The COAD box plot shows higher MYO5BP3 RNA expression in tumor versus normal tissue (log2 FC = +0.043, t-test p = .016).
This table shows molecular features associated with MYO5BP3 in patient tissues and cancer cell lines. In patient samples, MYO5BP3 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
